Prohost Biotechnology

APRIL 16,2008

PROHOST FILTER

MIGRAINE 04/16/2008 The medical community has become increasingly aware that Inflammation might be playing an important role in many chronic and life-threatening diseases, including cancer. Capitalizing on this notion, Pozen and GlaxoSmithKline added an anti-inflammatory drug to a member of migraine-specific medicines. It worked. The firms were granted FDA approval for a new better acting migraine drug called Treximet.

PROMISING CANCER DRUGS 04/15/2008 Cancer drugs, Vaccines, predictive tests and other presentations. (Subscribers only)

MILLENNIUM: A TAKE OVER 04/10/2008 Knowing better than investors the value of Millennium Pharmaceuticals (MLNM), Takeda Pharmaceutical Co. has bid $8.8 billion on Millennium. Stock has crossed our $24 target.

ONCOPHAGE® (VITESPEN) VACCINE APPRO.... 04/08/2008 the Russian Ministry of Public Health has issued a registration certificate for the use of Oncophage® (vitespen) developed by Antigenics (AGEN) for the treatment of kidney cancer patients at intermediate risk for disease recurrence. The company expects to launch Oncophage in Russia in the second half of 2008.

SANGAMO BIOSCIENCES (SGMO) 04/07/2008 More and more scientists and drug developing firms, private and public, are becoming aware that Sangamo’s ZFP Nuclease (ZFN) platform might be the breakthrough that addresses many of the major problems hampering the success of biological science revolution.

VERTEX' DRUG FOR CYSTIC FIBROSIS 04/01/2008 Vertex Announces Positive Results for VX-770 - an oral Investigational Agent That Targets a defective protein responsible for cystic fibrosis

COMPUGEN: A MARKER IN MYOCARDIAL IN.... 04/01/2008 Compugen has provided the medical community with what confirms the value of its predictive discovery platforms. This capability has begun to bring in new valuable molecules, which were not previously known.

A NEW DRUG TO DIMINISH HIV RESISTAN.... 03/31/2008 A broad-spectrum antiviral product candidate might suppress HIV resistance to nucleoside reverse transcriptase inhibitors (NRTIs)

PRADAXA®: A NOVEL ANTICOAGULANT 03/28/2008 Pradaxa®, an oral direct thrombin inhibitor. The novel drug is approved in Europe to prevent venous thromboembolic events in adults who have undergone elective total hip or total knee replacement surgery.

THE PROHOST N-LETTER IS POSTED 03/27/2008 The Game. The biotech sector . The bad patterns. The rule of thumb and the biotech disciplines that will supervene. (FOR SUBSCRIBERS ONLY>)

DINAVAX (DVAX) AND MERCK 03/18/2008 While receiving an investigational hepatitis B vaccine, one individual among 2500 vaccinated with 5000 doses of the HEPLISAV vaccine co-developed by Dynavax and Merck was diagnosed with Wegener\'s granulomatosis,

GENTA'S DRUG GENASENSE 03/17/2008 Genta\'s drug, Genasense inhibits Bcl-2, a protein that makes cancer resist chemotherapy.

GENENTECH'S YEAR AND YEARS 03/14/2008 It is, indeed, Genentech’s day, where the firm is expected to project 2008 profit outlook between $3.30 and $3.45 per share, its Avastin\'s unprecedented sales growth, its pipeline and its plans for the future.

PDL BIOPHARMACEUTICALS 03/05/2008 \"To sell ourselves, or not to sell ourselves\", this is the question. \"We want to sell, but we could not sell\", this is the cause of investors\' catastrophic losses. The story repeats itself with different star players. Is it time to buy now, or to think about it? What other biotechnology made us decide to buy without thinking? Read the answer in the upcoming Prohost letter.

REWRITING THE TEXT BOOKS? 03/03/2008 The market first. Then news from Vanda (VNDA) which insinuates that as a developer of antipsychotic and neurological products, especially of an antipsychotic drug waiting for approval, this firm is doing its homework.

GENENTECH: THE GIANT SUPERVENED 02/22/2008 We said it on February 15. It happened on February 22. The FDA granted Avastin accelerated approval to protect women from breast cancer spread and protect investors from the market's parasites.

ONYX (ONXX) A BUY OPPORTUNITY 02/19/2008 The irrational selling of the stock offers an opportunity for those who had missed buying the stock and another opportunity to accumulate by the firm’s fans.

ADVANCED PROSTATE CANCER: A NEW HOP.... 02/16/2008 A private biotech and a publicly traded biotech firm might have good news for hormone refractory prostate cancer. For subscribers only.

CORRECTING HYPONATREMIA 02/16/2008 Low serum sodium (hyponatremia) is a complication of heart failure and can also occur in patients with cirrhosis or syndrome of inappropriate anti-diuretic hormone secretion (SIADH). At least a quarter of patients with heart failure have hyponatremia. Recent studies have demonstrated that low sodium levels are an independent predictor of worsening outcomes in heart failure patients.

GIANTS AND DWARFS 02/15/2008 Genentech\'s management has proven time and time again it is a giant. That\'s why we never lost faith in this firm\'s unparalleled capability to grow.

deCODE: SNP PROSTATE CA TEST LAUNCH.... 02/14/2008 We are at the age of personalized medicine. deCODE Genetics has launched a swab test that detects increased risk for prostate cancer. The event marks a new milestone in the fast evolution of biotechnology.

DENDREON\'S PROVENGE: PROMISING NEW.... 02/14/2008 Dendron releases promising data for its prostate cancer active immunotherapy Provenge.

GENENTECH: UNNECESSARY DEBATE. 02/13/2008 Avastin is already

a blockbuster. Why making a fuss out of its approval for breast cancer?

COMPUGEN: TIME FOR RECOGNITION 02/12/2008 Compugen took

time to build its strong engines. Has time come to reap the fruits.

OTHER RECENT COMMENTS

VERTEX AND HCV PROTEASE INHIBITOR (For subscribers only)

PROVENGE AGAIN

THE FDA AND PROVENGE

MILLENNIUM QUARTERLY RESULTS

GENETIC ORIGIN OF DISEASES

TYSABRI®